Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 10(1): 5191, 2019 11 15.
Article in English | MEDLINE | ID: mdl-31729360

ABSTRACT

Histone H2AX and MDC1 are key DNA repair and DNA-damage signalling proteins. When DNA double-strand breaks (DSBs) occur, H2AX is phosphorylated and then recruits MDC1, which in turn serves as a docking platform to promote the localization of other factors, including 53BP1, to DSB sites. Here, by using CRISPR-Cas9 engineered human cell lines, we identify a hitherto unknown, H2AX-independent, function of MDC1 mediated by its PST-repeat region. We show that the PST-repeat region directly interacts with chromatin via the nucleosome acidic patch and mediates DNA damage-independent association of MDC1 with chromatin. We find that this region is largely functionally dispensable when the canonical γH2AX-MDC1 pathway is operative but becomes critical for 53BP1 recruitment to DNA-damage sites and cell survival following DSB induction when H2AX is not available. Consequently, our results suggest a role for MDC1 in activating the DDR in areas of the genome lacking or depleted of H2AX.


Subject(s)
Adaptor Proteins, Signal Transducing/chemistry , Adaptor Proteins, Signal Transducing/metabolism , Cell Cycle Proteins/chemistry , Cell Cycle Proteins/metabolism , Chromatin/metabolism , DNA Damage , Histones/metabolism , Adaptor Proteins, Signal Transducing/genetics , Amino Acid Motifs , Cell Cycle Proteins/genetics , Cell Line , Chromatin/genetics , DNA Breaks, Double-Stranded , DNA Repair , Histones/genetics , Humans , Tumor Suppressor p53-Binding Protein 1/genetics , Tumor Suppressor p53-Binding Protein 1/metabolism
2.
Nat Commun ; 10(1): 87, 2019 01 08.
Article in English | MEDLINE | ID: mdl-30622252

ABSTRACT

Mutations in the ATM tumor suppressor gene confer hypersensitivity to DNA-damaging chemotherapeutic agents. To explore genetic resistance mechanisms, we performed genome-wide CRISPR-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan. Thus, we here establish that inactivating terminal components of the non-homologous end-joining (NHEJ) machinery or of the BRCA1-A complex specifically confer topotecan resistance to ATM-deficient cells. We show that hypersensitivity of ATM-mutant cells to topotecan or the poly-(ADP-ribose) polymerase (PARP) inhibitor olaparib reflects delayed engagement of homologous recombination at DNA-replication-fork associated single-ended double-strand breaks (DSBs), allowing some to be subject to toxic NHEJ. Preventing DSB ligation by NHEJ, or enhancing homologous recombination by BRCA1-A complex disruption, suppresses this toxicity, highlighting a crucial role for ATM in preventing toxic LIG4-mediated chromosome fusions. Notably, suppressor mutations in ATM-mutant backgrounds are different to those in BRCA1-mutant scenarios, suggesting new opportunities for patient stratification and additional therapeutic vulnerabilities for clinical exploitation.


Subject(s)
Antineoplastic Agents/pharmacology , Ataxia Telangiectasia Mutated Proteins/genetics , DNA End-Joining Repair/genetics , Drug Resistance, Neoplasm/genetics , Animals , Antineoplastic Agents/therapeutic use , Ataxia Telangiectasia Mutated Proteins/metabolism , BRCA1 Protein/metabolism , CRISPR-Cas Systems/genetics , Cell Line, Tumor , Cell Survival/genetics , DNA Breaks, Double-Stranded/drug effects , DNA Ligase ATP/metabolism , DNA Replication/drug effects , DNA Replication/genetics , Female , Humans , Mice , Mice, Inbred NOD , Mice, Knockout , Mouse Embryonic Stem Cells , Mutation , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Phthalazines/pharmacology , Phthalazines/therapeutic use , Piperazines/pharmacology , Piperazines/therapeutic use , Topotecan/pharmacology , Topotecan/therapeutic use
3.
Nat Cell Biol ; 20(8): 954-965, 2018 08.
Article in English | MEDLINE | ID: mdl-30022119

ABSTRACT

BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient breast cancer cells treated with PARP inhibitors. We identified two previously uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers strong PARP-inhibitor resistance. Mechanistically, we show that C20orf196 and FAM35A form a complex, 'Shieldin' (SHLD1/2), with FAM35A interacting with single-stranded DNA through its C-terminal oligonucleotide/oligosaccharide-binding fold region. We establish that Shieldin acts as the downstream effector of 53BP1/RIF1/MAD2L2 to promote DNA double-strand break (DSB) end-joining by restricting DSB resection and to counteract homologous recombination by antagonizing BRCA2/RAD51 loading in BRCA1-deficient cells. Notably, Shieldin inactivation further sensitizes BRCA1-deficient cells to cisplatin, suggesting how defining the SHLD1/2 status of BRCA1-deficient tumours might aid patient stratification and yield new treatment opportunities. Highlighting this potential, we document reduced SHLD1/2 expression in human breast cancers displaying intrinsic or acquired PARP-inhibitor resistance.


Subject(s)
BRCA1 Protein/genetics , Bone Neoplasms/drug therapy , Breast Neoplasms/drug therapy , DNA End-Joining Repair , Drug Resistance, Neoplasm , Osteosarcoma/drug therapy , Ovarian Neoplasms/drug therapy , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Proteins/metabolism , Recombinational DNA Repair , Animals , BRCA1 Protein/deficiency , Bone Neoplasms/genetics , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Cell Cycle Proteins , Cell Line, Tumor , Cisplatin/pharmacology , DNA Breaks, Double-Stranded , DNA-Binding Proteins , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm/genetics , Female , HEK293 Cells , Humans , Mad2 Proteins/genetics , Mad2 Proteins/metabolism , Mice , Multiprotein Complexes , Osteosarcoma/genetics , Osteosarcoma/metabolism , Osteosarcoma/pathology , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Proteins/genetics , Telomere-Binding Proteins/genetics , Telomere-Binding Proteins/metabolism , Tumor Suppressor p53-Binding Protein 1/genetics , Tumor Suppressor p53-Binding Protein 1/metabolism , Xenograft Model Antitumor Assays
4.
Nat Commun ; 9(1): 1700, 2018 04 27.
Article in English | MEDLINE | ID: mdl-29703891

ABSTRACT

Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare, but devastating genetic disease characterized by segmental premature aging, with cardiovascular disease being the main cause of death. Cells from HGPS patients accumulate progerin, a permanently farnesylated, toxic form of Lamin A, disrupting the nuclear shape and chromatin organization, leading to DNA-damage accumulation and senescence. Therapeutic approaches targeting farnesylation or aiming to reduce progerin levels have provided only partial health improvements. Recently, we identified Remodelin, a small-molecule agent that leads to amelioration of HGPS cellular defects through inhibition of the enzyme N-acetyltransferase 10 (NAT10). Here, we show the preclinical data demonstrating that targeting NAT10 in vivo, either via chemical inhibition or genetic depletion, significantly enhances the healthspan in a Lmna G609G HGPS mouse model. Collectively, the data provided here highlights NAT10 as a potential therapeutic target for HGPS.


Subject(s)
Aging, Premature/drug therapy , Genomic Instability/drug effects , Hydrazones/pharmacology , N-Terminal Acetyltransferase A/antagonists & inhibitors , Progeria/drug therapy , Thiazoles/pharmacology , Aging, Premature/genetics , Aging, Premature/mortality , Aging, Premature/pathology , Animals , DNA Damage/drug effects , DNA Damage/genetics , Disease Models, Animal , Female , Genomic Instability/genetics , Humans , Hydrazones/therapeutic use , Kaplan-Meier Estimate , Lamin Type A/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , N-Terminal Acetyltransferase A/genetics , N-Terminal Acetyltransferase A/metabolism , N-Terminal Acetyltransferases , Progeria/genetics , Progeria/mortality , Progeria/pathology , Thiazoles/therapeutic use
5.
Sci Rep ; 6: 24356, 2016 Apr 15.
Article in English | MEDLINE | ID: mdl-27079678

ABSTRACT

The RNA-guided Cas9 nuclease is being widely employed to engineer the genomes of various cells and organisms. Despite the efficient mutagenesis induced by Cas9, off-target effects have raised concerns over the system's specificity. Recently a "double-nicking" strategy using catalytic mutant Cas9(D10A) nickase has been developed to minimise off-target effects. Here, we describe a Cas9(D10A)-based screening approach that combines an All-in-One Cas9(D10A) nickase vector with fluorescence-activated cell sorting enrichment followed by high-throughput genotypic and phenotypic clonal screening strategies to generate isogenic knockouts and knock-ins highly efficiently, with minimal off-target effects. We validated this approach by targeting genes for the DNA-damage response (DDR) proteins MDC1, 53BP1, RIF1 and P53, plus the nuclear architecture proteins Lamin A/C, in three different human cell lines. We also efficiently obtained biallelic knock-in clones, using single-stranded oligodeoxynucleotides as homologous templates, for insertion of an EcoRI recognition site at the RIF1 locus and introduction of a point mutation at the histone H2AFX locus to abolish assembly of DDR factors at sites of DNA double-strand breaks. This versatile screening approach should facilitate research aimed at defining gene functions, modelling of cancers and other diseases underpinned by genetic factors, and exploring new therapeutic opportunities.


Subject(s)
CRISPR-Cas Systems , Deoxyribonuclease I/genetics , Deoxyribonuclease I/metabolism , Gene Editing , Genotype , Phenotype , Alleles , Base Sequence , Cell Line , Drug Discovery , Gene Knockout Techniques , Gene Order , Gene Targeting , Genetic Loci , Genetic Vectors/genetics , Genomics/methods , High-Throughput Screening Assays , Humans , Mutagenesis , RNA, Guide, Kinetoplastida , Vascular Endothelial Growth Factor A/genetics
6.
Nat Cell Biol ; 17(11): 1458-1470, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26502057

ABSTRACT

Ubiquitylation is crucial for proper cellular responses to DNA double-strand breaks (DSBs). If unrepaired, these highly cytotoxic lesions cause genome instability, tumorigenesis, neurodegeneration or premature ageing. Here, we conduct a comprehensive, multilayered screen to systematically profile all human ubiquitin E2 enzymes for impacts on cellular DSB responses. With a widely applicable approach, we use an exemplary E2 family, UBE2Ds, to identify ubiquitylation-cascade components downstream of E2s. Thus, we uncover the nuclear E3 ligase RNF138 as a key homologous recombination (HR)-promoting factor that functions with UBE2Ds in cells. Mechanistically, UBE2Ds and RNF138 accumulate at DNA-damage sites and act at early resection stages by promoting CtIP ubiquitylation and accrual. This work supplies insights into regulation of DSB repair by HR. Moreover, it provides a rich information resource on E2s that can be exploited by follow-on studies.


Subject(s)
Carrier Proteins/metabolism , Nuclear Proteins/metabolism , Recombinational DNA Repair , Ubiquitin-Conjugating Enzymes/metabolism , Ubiquitin-Protein Ligases/metabolism , Carrier Proteins/genetics , Cell Cycle/genetics , Cell Line, Tumor , Cell Survival/genetics , DNA Breaks, Double-Stranded/drug effects , DNA Breaks, Double-Stranded/radiation effects , Endodeoxyribonucleases , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HEK293 Cells , Humans , Immunoblotting , Microscopy, Confocal , Nuclear Proteins/genetics , RNA Interference , Ubiquitin-Conjugating Enzymes/genetics , Ubiquitin-Protein Ligases/genetics , Ubiquitination
7.
Nat Struct Mol Biol ; 22(2): 150-157, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25558984

ABSTRACT

Mammalian CtIP protein has major roles in DNA double-strand break (DSB) repair. Although it is well established that CtIP promotes DNA-end resection in preparation for homology-dependent DSB repair, the molecular basis for this function has remained unknown. Here we show by biophysical and X-ray crystallographic analyses that the N-terminal domain of human CtIP exists as a stable homotetramer. Tetramerization results from interlocking interactions between the N-terminal extensions of CtIP's coiled-coil region, which lead to a 'dimer-of-dimers' architecture. Through interrogation of the CtIP structure, we identify a point mutation that abolishes tetramerization of the N-terminal domain while preserving dimerization in vitro. Notably, we establish that this mutation abrogates CtIP oligomer assembly in cells, thus leading to strong defects in DNA-end resection and gene conversion. These findings indicate that the CtIP tetramer architecture described here is essential for effective DSB repair by homologous recombination.


Subject(s)
Carrier Proteins/chemistry , Carrier Proteins/metabolism , Nuclear Proteins/chemistry , Nuclear Proteins/metabolism , Protein Multimerization/physiology , Crystallography, X-Ray , DNA Breaks, Double-Stranded , DNA Repair/physiology , Endodeoxyribonucleases , Humans
8.
Science ; 344(6183): 527-32, 2014 May 02.
Article in English | MEDLINE | ID: mdl-24786082

ABSTRACT

Down-regulation and mutations of the nuclear-architecture proteins lamin A and C cause misshapen nuclei and altered chromatin organization associated with cancer and laminopathies, including the premature-aging disease Hutchinson-Gilford progeria syndrome (HGPS). Here, we identified the small molecule "Remodelin" that improved nuclear architecture, chromatin organization, and fitness of both human lamin A/C-depleted cells and HGPS-derived patient cells and decreased markers of DNA damage in these cells. Using a combination of chemical, cellular, and genetic approaches, we identified the acetyl-transferase protein NAT10 as the target of Remodelin that mediated nuclear shape rescue in laminopathic cells via microtubule reorganization. These findings provide insights into how NAT10 affects nuclear architecture and suggest alternative strategies for treating laminopathies and aging.


Subject(s)
Cell Nucleus/drug effects , Enzyme Inhibitors/pharmacology , Hydrazones/pharmacology , N-Terminal Acetyltransferase E/antagonists & inhibitors , Progeria/enzymology , Thiazoles/pharmacology , Cell Line, Tumor , Cell Nucleus/genetics , Cell Nucleus/ultrastructure , Chromatin/metabolism , Enzyme Inhibitors/chemistry , Humans , Hydrazones/chemistry , Lamin Type A/genetics , Microtubules/metabolism , N-Terminal Acetyltransferase E/chemistry , N-Terminal Acetyltransferase E/genetics , N-Terminal Acetyltransferases , Nocodazole/pharmacology , Progeria/genetics , Protein Structure, Tertiary , RNA, Small Interfering/genetics , Thiazoles/chemistry
9.
Biochim Biophys Acta ; 1610(1): 124-32, 2003 Feb 17.
Article in English | MEDLINE | ID: mdl-12586386

ABSTRACT

Voltage-gated potassium channels control the membrane potential of excitable cells. To understand their function, knowledge of their structure is essential. However, these channels are scarce in natural sources, and overexpression is necessary to generate material for structural studies. We have compared functional expression of the Drosophila Shaker H4 potassium channel in stable insect cell lines and in baculovirus-infected insect cells, using three different baculovirus promoters. Stable insect cell lines expressed correctly assembled channel, which was glycosylated and found predominantly at, or close to, the cell surface. In comparison, the majority of baculovirus-overexpressed Shaker was intracellular and incorrectly assembled. The proportion of functional Shaker increased, however, if the weaker basic protein promoter was used rather than the stronger p10 or polyhedrin promoters. In addition, co-expression of the molecular chaperone, calnexin, increased the quantity of correctly assembled channel protein, suggesting that calnexin can be used to increase the efficiency of channel expression in insect cells.


Subject(s)
Calnexin/biosynthesis , Potassium Channels/biosynthesis , Animals , Baculoviridae/genetics , Calnexin/genetics , Cell Line , Drosophila Proteins , Gene Expression Regulation/drug effects , Insecta , Molecular Chaperones/pharmacology , Potassium Channels/genetics , Promoter Regions, Genetic , Shaker Superfamily of Potassium Channels , Transfection , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...